Abstract: The present invention provides nucleic acid and protein sequences for a novel Th-1 cell-specific protein, Chandra. The herein-disclosed sequences can be used for any of a number of purposes, including for the specific detection of Th1 lymphocytes, for the identification of molecules that associate with and/or modulate the activity of Chandra, to diagnose any of a number of conditions associated with Th1 or Th2 cell activity, or to modulate the number and/or activity of Th1 or Th2 lymphocytes in a mammal.

Abstract: A packaging assembly for a hydrophilic catheter permits activation of a hydrophilic coating on the catheter and introduction of the catheter into a urethra in a sterile condition. A rupturable pouch containing a lubricant is enclosed in a chamber of the packaging assembly also occupied by the catheter. A portion of the packaging assembly in which the pouch is disposed is removable from the remaining portion of the packaging assembly following activation of the hydrophilic coating, such as by tearing along a line beginning at one or more tear notches, ripping along a perforation, cutting, or some combination thereof. The remaining portion of the packaging assembly may then be manipulated to introduce the catheter into a urethra, isolating at least an insertable portion of the catheter from human hands prior to contact with the urethra.

Abstract: The present invention provides nucleic acid and protein sequences for a novel Th-1 cell-specific protein, Chandra. The herein-disclosed sequences can be used for any of a number of purposes, including for the specific detection of Th1 lymphocytes, for the identification of molecules that associate with and/or modulate the activity of Chandra, to diagnose any of a number of conditions associated with Th1 or Th2 cell activity, or to modulate the number and/or activity of Th1 or Th2 lymphocytes in a mammal.

Abstract: The present invention provides nucleic acid and protein sequences for a Th-1 cell-specific protein, Chandra. The herein-disclosed sequences can be used for any of a number of purposes, including for the specific detection of Th1 lymphocytes, for the identification of molecules that associate with and/or modulate the activity of Chandra, to diagnose any of a number of conditions associated with Th1 or Th2 cell activity, or to modulate the number and/or activity of Th1 or Th2 lymphocytes in a mammal.

Abstract: The invention provides methods and compositions relating to interleukin 2 signal transducers, particularly an isolated human signal transducer and activator of transcription 5 (hStat 5), or a fragment thereof having an hStat 5-specific binding affinity, nucleic acids encoding hStat 5, which nucleic acids may be part of hStat 5-expression vectors and may be incorporated into a recombinant cell, agents which selectively bind hStat 5 or hStat 5 intracellular binding targets, or disrupt the binding of hStat 5 to such intracellular targets, methods of making such agents and hStat 5-specific binding targets in the form of cell surface proteins and nucleic acids. An hStat 5 drug screening assay involves forming mixtures of an hStat 5, an intracellular hStat 5 binding target, and a prospective agent at different concentrations. The mixtures are incubated to permit the binding of the intracellular hStat 5 binding target to the hStat 5 and the mixtures are then analyzed for the presence of such binding.